logo
Liberty All-Star ® Growth Fund, Inc. June 2025 Monthly Update

Liberty All-Star ® Growth Fund, Inc. June 2025 Monthly Update

Business Wire3 days ago
BOSTON--(BUSINESS WIRE)--Below is the June 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG).
Liberty All-Star Growth Fund, Inc.
Ticker: ASG
Monthly Update, June 2025
Investment Approach:
Fund Style: All-Cap Growth
Fund Strategy: Combines three growth style investment managers, each with a distinct capitalization focus (small-, mid- and large-cap) selected and continuously monitored by the Fund's Investment Advisor.
Investment Managers:
Weatherbie Capital, LLC
Small-Cap Growth
Congress Asset Management Company, LLP
Mid-Cap Growth
Westfield Capital Management Company, L.P.
Large-Cap Growth
Top 20 Holdings at Month-End:
(37.3% of equity portfolio)
1
NVIDIA Corp.
4.7%
2
Microsoft Corp.
3.1%
3
Apple, Inc.
2.5%
4
Amazon.com, Inc.
2.4%
5
Meta Platforms, Inc.
2.4%
6
Ollie's Bargain Outlet Holdings, Inc.
2.4%
7
Natera, Inc.
1.8%
8
FirstService Corp.
1.8%
9
Casella Waste Systems, Inc.
1.6%
10
Alphabet, Inc.
1.6%
11
Visa, Inc.
1.5%
12
SPS Commerce, Inc.
1.4%
13
Dexcom, Inc.
1.4%
14
Netflix, Inc.
1.4%
15
ACADIA Pharmaceuticals, Inc.
1.3%
16
AAR Corp.
1.2%
17
Upstart Holdings, Inc.
1.2%
18
Broadcom Inc.
1.2%
19
Ascendis Pharma A/S
1.2%
20
SiteOne Landscape Supply, Inc.
1.2%
Expand
Holdings are subject to change.
Monthly Performance:
Performance
NAV
Market Price
Discount
Beginning of month value
$5.64
$5.20
-7.8%
End of month value
$5.93
$5.47
-7.8%
Performance for month
5.14%
5.19%
Performance year-to-date
1.27%
0.86%
Expand
Net Assets at Month-End ($millions):
Total
$367.5
Equities
$360.6
Percent Invested
98.1%
Expand
Sector Breakdown* (% of equity portfolio):
Information Technology
29.6%
Industrials
20.0%
Health Care
15.6%
Consumer Discretionary
10.8%
Financials
10.6%
Communication Services
7.0%
Consumer Staples
3.5%
Real Estate
1.8%
Materials
0.9%
Energy
0.2%
Total Market Value
100.0%
Expand
*Based on Standard & Poor's and MSCI Global Industry Classification Standard (GICS).
New Holdings:
Applied Materials, Inc.
Cava Group, Inc.
Cloudflare, Inc.
HEICO Corp.
Howmet Aerospace, Inc.
O'Reilly Automotive, Inc.
Spotify Technology SA
Synopsys, Inc.
Holdings Liquidated:
BILL Holdings, Inc.
Camtek, Ltd./Israel
Copart, Inc.
Ionis Pharmaceuticals, Inc.
Lam Research Corp.
MongoDB, Inc.
Onto Innovation, Inc.
The net asset value (NAV) of a closed-end fund is the market value of the underlying investments (i.e., stocks and bonds) in the Fund's portfolio, minus liabilities, divided by the total number of Fund shares outstanding. However, the Fund also has a market price; the value at which it trades on an exchange. If the market price is above the NAV the Fund is trading at a premium. If the market price is below the NAV the Fund is trading at a discount.
Performance returns for the Fund are total returns, which includes dividends, and are net of management fees and other Fund expenses. Returns are calculated assuming that a shareholder reinvested all distributions. Past performance cannot predict future investment results.
Performance will fluctuate with changes in market conditions. Current performance may be lower or higher than the performance data shown. Performance information shown does not reflect the deduction of taxes that shareholders would pay on Fund distributions or the sale of Fund shares. Shareholders must be willing to tolerate significant fluctuations in the value of their investment. An investment in the Fund involves risk, including loss of principal.
Sources of distributions to shareholders may include ordinary dividends, long-term capital gains and return of capital. The final determination of the source of all distributions in 2025 for tax reporting purposes will be made after year end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during its fiscal year and may be subject to changes based on tax regulations. Based on current estimates a portion of the distributions consist of a return of capital. These estimates may not match the final tax characterization (for the full year's distributions) contained in shareholder 1099-DIV forms after the end of the year.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rexford Industrial Realty (REXR) Gets a Buy from Colliers Securities
Rexford Industrial Realty (REXR) Gets a Buy from Colliers Securities

Business Insider

time35 minutes ago

  • Business Insider

Rexford Industrial Realty (REXR) Gets a Buy from Colliers Securities

In a report released today, Barry Oxford from Colliers Securities maintained a Buy rating on Rexford Industrial Realty, with a price target of $41.00. The company's shares closed today at $36.32. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Oxford covers the Real Estate sector, focusing on stocks such as Centerspace, Rexford Industrial Realty, and Global Medical REIT. According to TipRanks, Oxford has an average return of 0.4% and a 49.48% success rate on recommended stocks. In addition to Colliers Securities, Rexford Industrial Realty also received a Buy from TR | OpenAI – 4o's Gavin Stockmere in a report issued today. However, on July 9, BMO Capital maintained a Hold rating on Rexford Industrial Realty (NYSE: REXR). The company has a one-year high of $52.61 and a one-year low of $29.68. Currently, Rexford Industrial Realty has an average volume of 2.85M.

Bernstein Remains a Buy on Humana (HUM)
Bernstein Remains a Buy on Humana (HUM)

Business Insider

time35 minutes ago

  • Business Insider

Bernstein Remains a Buy on Humana (HUM)

In a report released yesterday, Lance Wilkes from Bernstein maintained a Buy rating on Humana, with a price target of $269.00. The company's shares closed yesterday at $226.56. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Centene, and Humana. According to TipRanks, Wilkes has an average return of -4.9% and a 37.50% success rate on recommended stocks. In addition to Bernstein, Humana also received a Buy from RBC Capital's Ben Hendrix in a report issued on July 14. However, yesterday, Truist Financial maintained a Hold rating on Humana (NYSE: HUM).

Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With Novo
Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With Novo

Yahoo

time37 minutes ago

  • Yahoo

Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With Novo

We recently published . Hims & Hers Health, Inc. (NYSE:HIMS) is one of Monday's top performers. Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working with Novo Nordisk in the future despite the termination of its earlier partnership. Novo Nordisk, maker of blockbuster drugs Wegovy and Ozempic, terminated its deal with Hims & Hers Health, Inc. (NYSE:HIMS) in June over allegations that the latter failed to adhere to federal laws that prohibit mass sales of compounded drugs under the false guise of 'personalization.' Hims & Hers Health, Inc. (NYSE:HIMS) has been selling knockoff versions of the drugs for years amid strong demand, but was this year ordered by the Food and Drug Administration (FDA) to stop due to a now sufficient supply. A nurse in a telehealth platform talking with a patient on video call for consultation. After the termination, Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum said he was upset that Novo Nordisk felt the pressure over the knockoff version, but said that there was 'no way in hell we're going to cave on that.' Based on its historical reporting dates, Hims & Hers Health, Inc. (NYSE:HIMS) will report its earnings results for the second quarter in the first week of August 2025. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store